Cambridge, Ma., USA - January 3, 2014, Cambridge, Ma., USA - Eleven Biotherapeutics, a biopharmaceutical company, appoints Gregory D. Perry as chief financial and business officer, Daniel S. Lynch as chairman of the board of directors and Jane Pritchett Henderson as a member of the board.
Article continues below
Prior to joining Eleven Biotherapeutics, Mr. Perry served as Interim Chief Financial Officer of InVivo Therapeutics. Prior to InVivo, Mr. Perry was Executive Vice President and Chief Financial Officer of Immunogen, Inc. from 2009 to 2013, where he led the company's strategic transition from a platform technology company to a product development company.
Prior to Immunogen, Mr. Perry served as Chief Financial Officer of Elixir Pharmaceuticals. He served as CFO of Domantis, Ltd. until its acquisition by GlaxoSmithKline in 2006, and as CFO of Transkaryotic Therapies, Inc. until its acquisition by Shire plc in 2005.
Before joining Transkaryotic Therapies in 2003, he served in financial management positions of increasing responsibility at PerkinElmer, Inc., Honeywell and GE's European medical systems business unit. Mr. Perry holds a Bachelor of Arts degree in Economics and in Political Science from Amherst College.
Mr. Lynch spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, including securing FDA approval of ERBITUX (Cetuximab), an important new cancer treatment. As CFO, he led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb.
Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December, 2010, when it was acquired by McKesson. More recently he was Executive Chairman of the board for Avila Therapeutics and Stromedix.
In addition to Eleven Biotherapeutics, Mr. Lynch is currently a member of the board of directors for BIND Therapeutics, bluebird bio, Blueprint Medicines, Nimbus Discovery and RaNA Therapeutics. He received his BA in Mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Ms. Pritchett Henderson is Senior Vice President and Chief Business Officer at Kolltan Pharmaceuticals. Prior to joining Kolltan, she served as Vice President, Business Development at ISTA Pharmaceuticals, Inc., where she managed the process that culminated in the acquisition of ISTA by Bausch + Lomb. She also oversaw the identification and evaluation of acquisitions and licensing opportunities and intellectual property strategy at ISTA. ■